BARDA contract worth up to $89M will support Basilea antibiotic

06/25/2013 | RTT News

The Biomedical Advanced Research and Development Authority granted Basilea Pharmaceutica a six-year contract worth as much as $89 million to support development of its novel monosulfactam antibiotic BAL30072. The drug, which is under development for severe infections, was chosen because of its broad coverage against multidrug-resistant Gram-negative pathogens. Basilea initially will get $17 million over 22 months.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA